NCT05207761

Study to Evaluate Drug-drug Interaction, Safety and Tolerability in Case of the Co-administration of D565 and D930

A Randomized, Open-label, 2-period, Parallel Group, Multiple-dose Phase 1 Study to Evaluate Drug-drug Interaction, Safety and Tolerability in Case of the Co-administration of D565 and D930, in Healthy Male Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: Chong Kun Dang Pharmaceutical · Industry
• Sex: Male
• Age: 19 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This study is a randomized, open-label, 2-period, parallel group, multiple-dose phase 1 study to evaluate drug-drug Interaction, safety and tolerability in case of the co-administration of D565 and D930, in healthy male subjects

Detailed description

To healthy male subjects of thirty-two (32), Investigational products are administered following treatments in each period

Conditions

• Glaucoma

Interventions

Type	Name	Description
DRUG	D565	Q.D. in both eye
DRUG	D930	T.I.D in both eye

Timeline

• Start date: 2022-01-19
• Primary completion: 2022-10-18
• Completion: 2022-11-02
• First posted: 2022-01-26
• Last updated: 2023-01-05

Locations

1 site across 1 country: South Korea